Amanda Ralabate

1.6k total citations
5 papers, 426 citations indexed

About

Amanda Ralabate is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amanda Ralabate has authored 5 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amanda Ralabate's work include Melanoma and MAPK Pathways (4 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Brain Metastases and Treatment (2 papers). Amanda Ralabate is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Brain Metastases and Treatment (2 papers). Amanda Ralabate collaborates with scholars based in United States. Amanda Ralabate's co-authors include Harriet M. Kluger, Mario Sznol, Veronica Chiang, Justine V. Cohen, Lucia B. Jilaveanu, Amit Mahajan, Sarah B. Goldberg, Upendra P. Hegde, Matthew M. Burke and Thuy Tran and has published in prestigious journals such as Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Amanda Ralabate

5 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amanda Ralabate United States	5	376	192	138	115	66	5	426
J. P. Bizzari France	8	227 0.6×	117 0.6×	48 0.3×	173 1.5×	60 0.9×	10	340
Dina Pietrangelo United States	3	311 0.8×	125 0.7×	124 0.9×	40 0.3×	17 0.3×	4	345
J.C. Hassel Germany	8	243 0.6×	31 0.2×	86 0.6×	104 0.9×	25 0.4×	16	278
Michela Palleschi Italy	9	189 0.5×	133 0.7×	38 0.3×	75 0.7×	41 0.6×	46	281
Gary Simmons United States	9	169 0.4×	63 0.3×	31 0.2×	144 1.3×	41 0.6×	22	291
Adrien Costantini France	10	279 0.7×	146 0.8×	95 0.7×	120 1.0×	13 0.2×	25	402
Zul Fazreen Singapore	6	282 0.8×	122 0.6×	167 1.2×	72 0.6×	10 0.2×	8	391
Chris Hopson United States	2	296 0.8×	41 0.2×	143 1.0×	140 1.2×	9 0.1×	3	363
J. Infante United States	8	137 0.4×	66 0.3×	30 0.2×	156 1.4×	15 0.2×	17	273

Countries citing papers authored by Amanda Ralabate

Since Specialization

Citations

This map shows the geographic impact of Amanda Ralabate's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda Ralabate with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda Ralabate more than expected).

Fields of papers citing papers by Amanda Ralabate

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda Ralabate. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda Ralabate. The network helps show where Amanda Ralabate may publish in the future.

Co-authorship network of co-authors of Amanda Ralabate

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda Ralabate. A scholar is included among the top collaborators of Amanda Ralabate based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda Ralabate. Amanda Ralabate is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Kluger, Harriet M., Veronica Chiang, Amit Mahajan, et al.. (2018). Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. Journal of Clinical Oncology. 37(1). 52–60. 197 indexed citations

2.

Kluger, Harriet M., Sarah B. Goldberg, Mario Sznol, et al.. (2015). Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases.. Journal of Clinical Oncology. 33(15_suppl). 9009–9009. 31 indexed citations

3.

Sznol, Mario, Harriet M. Kluger, Margaret K. Callahan, et al.. (2014). Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).. Journal of Clinical Oncology. 32(18_suppl). LBA9003–LBA9003. 63 indexed citations

4.

Kluger, Harriet M., Mario Sznol, Margaret K. Callahan, et al.. (2014). Survival, Response Duration, and Activity By Braf Mutation (Mt) Status in a Phase 1 Trial of Nivolumab (Anti-Pd-1, Bms-936558, Ono-4538) and Ipilimumab (Ipi) Concurrent Therapy in Advanced Melanoma (Mel). Annals of Oncology. 25. iv374–iv374. 17 indexed citations

5.

Sznol, Mario, Harriet M. Kluger, Margaret K. Callahan, et al.. (2014). Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).. Journal of Clinical Oncology. 32(15_suppl). LBA9003–LBA9003. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact